Product Details
VOGLIBOSE 0.3 MG + GLIMEPIRIDE 2 MG + METFORMIN HYDROCHLORIDE 500 MG SR
Introduction : This combination of Voglibose 0.3 Mg + Glimepiride 2 Mg + Metformin Hydrochloride 500 Mg SR (sustained release) medication is indicated for the treatment of type 2 diabetes mellitus (T2DM) in adults to improve glycemic control when diet and exercise alone are not sufficient.
It is particularly useful for patients who require triple therapy with an alpha-glucosidase inhibitor (voglibose), a sulfonylurea (glimepiride), and a biguanide (metformin) to achieve target blood sugar levels.
Indication : Voglibose 0.3 Mg + Glimepiride 2 Mg + Metformin Hydrochloride 500 Mg SR tablet belongs to a category of medicines known as anti-diabetic drugs. It is a combination of medicines used to treat type 2 diabetes mellitus in adults. It helps control blood sugar levels in people with diabetes.
Keep taking this medicine, even if you feel well or your blood sugar levels are controlled. If you stop it without consulting your doctor, your blood sugar levels could rise and put you at risk of kidney damage, blindness, nerve problems and loss of limbs. Remember that it is only part of a treatment program that should also include a healthy diet, regular exercise, and weight reduction as advised by your doctor. Your lifestyle plays a big part in controlling diabetes.
Administration : It is typically taken orally with meals as directed by a healthcare professional.
or It is advised to take this medicine just before meals.
The dosage may vary, and it should be determined by a healthcare professional based on the patients individual needs and response to treatment.
Storage : Store the medication at room temperature, away from moisture, heat, and direct sunlight.
Keep the tablets in their original container, tightly closed, and out of reach of children.
Mechanism of Action : Voglibose inhibits alpha-glucosidase enzymes in the intestine, delaying the digestion and absorption of carbohydrates, which leads to reduced postprandial blood glucose levels.
Glimepiride stimulates insulin secretion from pancreatic beta cells by binding to ATP-sensitive potassium channels, thereby lowering blood sugar levels.
Metformin primarily works by reducing hepatic glucose production, enhancing insulin sensitivity in peripheral tissues, and improving glucose uptake by muscles, leading to reduced blood sugar levels.
Therapeutic : Anti Diabetic
Side Effects : Gastrointestinal disturbances such as nausea, vomiting, diarrhea, or abdominal discomfort
Hypoglycemia (low blood sugar levels) when used in combination with other antidiabetic medications
Headache
Allergic reactions or skin rash (rare)
Contraindications : Use of this medicine is not recommended during pregnancies as the possible effect on developing fetus is unknown. It is recommended to discontinue the consumption of this medicine if you are pregnant or planning to become pregnant. Consult your doctor before stopping the use of this medication so that an alternate medication can be prescribed.
Safety Advice / Warnings : Patients should be monitored regularly for signs of hypoglycemia, especially when Voglibose + Glimepiride + Metformin is used in combination with other antidiabetic medications.
This medication should be used with caution in patients with renal impairment, as metformin is primarily excreted by the kidneys, and dose adjustments may be necessary to prevent adverse effects.
Voglibose + Glimepiride + Metformin should not be used in patients with type 1 diabetes mellitus or diabetic ketoacidosis.
Patients should be advised to adhere to a regular meal schedule and monitor blood sugar levels closely while taking this medication
References : Voglibose: Uses, Interactions, Mechanism of Action | DrugBank Online
"Product Information: GLUCOPHAGE(R) oral tablets, metformin HCl oral tablets. Bristol-Myers Squibb Company (per FDA), Princeton, NJ, 2017.
Product Information: Metformin Juta oral tablet, metformin hydrochloride oral tablet. Juta Pharma GmbH (per AEMPS;Spain), Gutenbergstrasse 13, 24941 Flensburg, Germany, 2019."
Product Information: AMARYL(R) oral tablets, glimepiride oral tablets . Sanofi-Aventis U.S. LLC (per FDA), Bridgewater, NJ, 2016.
Badian M, Korn A, Lehr KH, et al: Determination of the absolute bioavailability of glimepiride (HOE 490), a new sulphonylurea. Int J Clin Pharmacol Ther Toxicol 1992; 30(11):481-482.